GNR-127

Phase 2Biologic

AAO GENERIUM

GNR-127 is one of 41 biologic programs targeting Allergic Rhinitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Singulair

OOrganon and Co

Approved

13 2

Flovent

PParatek Pharmaceuticals Inc

Approved

12 3

Xyzal

CChattem

Approved

11 4

Alvesco

AAzurity Pharmaceuticals

Approved

8 5

Claritin

PPerrigo Company

Approved

6 6

Zyrtec

KKenvue Brands

Approved

5 7

Pulmicort

SSalix

Approved

5 8

Clarinex

OOrganon and Co

Approved

5 9

Qvar

SSchering-Plough

Approved

4 10

Allegra

CChattem

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Allergic Rhinitis1 trial

A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.

Active, not recruiting·AAO GENERIUM·Phase 1/2·NCT07155499·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GNR-127. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNR-127 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNR-127. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AO GENERIUM company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: AAO GENERIUM

GNR-127

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Allergic Rhinitis1 trial

References

Drug Info

Quick Facts

Related News